The legal answer depends on the exact peptide product and how it is being marketed and dispensed
Therefore, since the early 1990s, we have presented stable gastric pentadecapeptide BPC 157, and its pleiotropic beneficial effects, acting also via the per oral route [3,4,5,6,7,8,9,10,11,12,13,14,16,17,18,19,20,21,22,23,24,27,28,29,30,31,32,34,37,39,40], as a late advantage of Robert and Szabos concept of cytoprotection [41,42,43,44,45,46,47,48,49]
The pushback was immediate
Members get access to detailed formulation comparisons, B12 monitoring templates, and personalized protocol recommendations that account for individual risk factors most resources simply ignore
Our guide to what a yes vote on BPC-157 means for your clinic covers the next steps in detail
Target Species